<DOC>
	<DOCNO>NCT02871427</DOCNO>
	<brief_summary>This study seek evaluate long-term safety effectiveness nelotanserin treatment visual hallucination ( VHs ) Rapid Eye Movement ( REM ) Sleep Behavior Disorder ( RBD ) subject Lewy body dementia ( LBD ) .</brief_summary>
	<brief_title>Open-label Study Nelotanserin Lewy Body Dementia With Visual Hallucinations REM Sleep Behavior Disorder</brief_title>
	<detailed_description>This multi-center open-label , long-term study LBD subject RBD and/or VHs . Eligible subject complete previous nelotanserin VH RBD study choose participate open-label study receive 20 , 40 , 60 , 80 mg nelotanserin daily 24 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Hallucinations</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>REM Sleep Behavior Disorder</mesh_term>
	<criteria>Subjects LBD complete previous nelotanserin VH RBD study Subjects current serious and/or unstable cardiovascular , respiratory , thyroid , gastrointestinal , renal , hematologic medical disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lewy body dementia</keyword>
	<keyword>Dementia Lewy body</keyword>
	<keyword>Parkinson 's disease dementia</keyword>
	<keyword>Visual hallucination</keyword>
	<keyword>REM sleep behavior disorder</keyword>
</DOC>